Home » Further delay for Shire's Adderall follow-up
Further delay for Shire's Adderall follow-up
U.S. regulators have asked that Shire include paediatric data in its resubmission of SHP 465 for attention-deficit hyperactivity disorder, throwing yet another obstacle in its bid for approval.
PharmaTimes
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May